FIELD: biotechnology; medicine.
SUBSTANCE: present invention to a murine monoclonal antibody capable of binding to rabies viruses or viruses related to rabies viruses, and neutralize these viruses, as well as to a cocktail of at least two monoclonal antibodies having said properties. Present invention also relates to a combination of a murine monoclonal antibody or a cocktail of at least two monoclonal antibodies and rabies vaccines for use in post-exposure prophylaxis (PEP) of rabies virus or rabies virus related viruses.
EFFECT: cocktail can neutralize a virus originating from such species as bats, dogs, cows, mongooses, skunks and wolves, and thus it can be used for treating a potentially infected patient.
10 cl, 1 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| THERAPEUTIC BIOPREPARATION FOR TREATING HEPATOCELLULAR CARCINOMA | 2014 |
|
RU2739218C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| RABIES VACCINE | 2014 |
|
RU2712743C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| CHIMERIC VACCINES BASED ON VIRUSES OF FLAVIVIRUS AND LYSSAVIRUS GENES | 2019 |
|
RU2816136C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
